RxDoctor Payments Data

Richard Weiss, MD

Cardiovascular Disease · Philadelphia, PANPI 1053343376

Payments from drug & device makers

$2,382in general payments, 2019–2025

Across 25 payments — averaging $95.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • GE HealthCare$293
  • Pfizer$92
  • Siemens Medical Solutions USA, Inc.$85
  • Shockwave Medical, Inc$47
  • Abiomed$16

What the payments were for

  • Travel & lodging$45219%
  • Food & beverage$1,93081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,382 in reported general payments places this provider in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$214,360
Medicare patients
1,499
Services billed
4,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban270$347,888
XareltoRivaroxaban159$202,643
Repatha SureclickEvolocumab239$174,732
EntrestoSacubitril/Valsartan91$145,996
FarxigaDapagliflozin Propanediol102$139,434
Praluent PenAlirocumab96$80,016
JardianceEmpagliflozin34$42,141
BrilintaTicagrelor19$19,660
MounjaroTirzepatide14$18,226
Rosuvastatin Calcium748$13,407
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid54$10,158
Metoprolol Succinate606$9,484
Atorvastatin Calcium687$9,073
Icosapent Ethyl19$7,156
Ezetimibe209$6,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$92$347,888270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →